27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biogen Inc (NASDAQ:BIIB) shares are up sharply Friday after the company announced a delay in the FDA decision for its Alzheimer's treatment candidate, aducanumab.
What Happened: The FDA has extended the review period for the biologic license application for aducanumab by three months, Biogen and Eisai Co., Ltd (OTC:ESALY) said in a statement.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Biogen is co-developing aducanumab with the Japanese pharma company.
Biogen, the sponsor of the BLA, said it submitted a response to an information request by the FDA that included additional analyses and clinical data. The regulatory agency, deeming the submission as a major amendment to the application, extended the review period to give time for review.
The PDUFA goal data now stands postponed from March 7 to June 7.
Why It's Important: The positive stock reaction to the delay in decision is apparently a relief rally, as investors were positioning for a rejection following a negative Adcom verdict issued in early November.
After nearly shelving the development of aducanumab for Alzheimer's disease, Biogen resurrected the clinical program following subset analysis of data.
The company made a regulatory submission in July and the FDA accepted the application for priority review in August, assigning a PDUFA goal date of March 7.
Analysts are optimistic that the drug will ultimately clear the regulatory hurdle, given there is a serious unmet need and that there are no FDA-approved therapies to treat the disease per se.
In premarket trading, Biogen shares were advancing 11.69% to $299.18 and Eisai was advancing 3.26% to $77.05.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.